Over 150 Total Lots Up For Auction at One Location - CA 05/31

Hyperfine targets European market with portable MR distributor partnerships

by HealthCare Business News | May 14, 2024
Business Affairs European News MRI
Hyperfine's portable Swoop MR scanner.
Hyperfine has announced new partnerships with distributors in France, the U.K., and Italy to extend the reach of its Swoop portable MR system across European markets. This expansion follows the company's receipt of CE certification under the EU MDR, and UKCA certification in the U.K. for its most advanced hardware and AI-powered software.

Swoop, unique for its portable and relatively inexpensive affordability, has a .064 Tesla magnet and requires no shielding. It is meant to enhance, and expand access to, brain imaging capabilities. The technology is particularly aimed at expanding clinical applications from hospital critical care units to outpatient clinics and medical offices, with potential use in treating conditions like Alzheimer’s disease and acute stroke.

“These strategic distributor partnerships enable a broader market footprint for our business beyond our direct commercial team in the U.S.,” said Maria Sainz, president and CEO of Hyperfine Inc. “We are very encouraged by the high interest level and positive feedback from international clinicians thus far.”
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

The Connecticut-based company has also expanded its leadership team, appointing industry veteran Enrico Barini as international business development director. Barini, who brings extensive experience from previous roles at ViewRay Inc. and Boston Scientific, will spearhead the Swoop system's market introduction in Europe.

Hyperfine's Swoop Portable MR Imaging system is the first of its kind to be FDA-cleared for brain imaging across all ages and is now commercially available in select markets. Its design enables diagnostic examination in locations where traditional MR imaging is unfeasible, thereby broadening the possibilities for patient care and clinical diagnosis.

Last month, the company launched a study to assess the effectiveness of Swoop for detecting amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients undergoing amyloid-targeting therapy aimed at reducing amyloid plaques in the brain.

You Must Be Logged In To Post A Comment